Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Published:2022-11 Issue:11 Volume:28 Page:2353-2363
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Jee Justin^ORCID,Lebow Emily S.,Yeh Randy^ORCID,Das Jeeban P.,Namakydoust Azadeh,Paik Paul K.,Chaft Jamie E.^ORCID,Jayakumaran Gowtham,Rose Brannon A.^ORCID,Benayed Ryma^ORCID,Zehir Ahmet^ORCID,Donoghue Mark,Schultz Nikolaus^ORCID,Chakravarty Debyani^ORCID,Kundra Ritika^ORCID,Madupuri Ramyasree,Murciano-Goroff Yonina R.,Tu Hai-Yan,Xu Chong-Rui^ORCID,Martinez Andrés,Wilhelm Clare,Galle Jesse,Daly Bobby,Yu Helena A.^ORCID,Offin Michael^ORCID,Hellmann Matthew D.,Lito Piro^ORCID,Arbour Kathryn C.^ORCID,Zauderer Marjorie G.^ORCID,Kris Mark G.,Ng Kenneth K.,Eng Juliana,Preeshagul Isabel,Victoria Lai W.,Fiore John J.,Iqbal Afsheen,Molena Daniela^ORCID,Rocco Gaetano,Park Bernard J.,Lim Lee P.,Li Mark,Tong-Li Candace^ORCID,De Silva Madhawa,Chan David L.,Diakos Connie I.,Itchins Malinda,Clarke Stephen^ORCID,Pavlakis Nick,Lee Adrian,Rekhtman Natasha,Chang Jason,Travis William D.,Riely Gregory J.,Solit David B.^ORCID,Gonen Mithat,Rusch Valerie W.,Rimner Andreas^ORCID,Gomez Daniel,Drilon Alexander^ORCID,Scher Howard I.,Shah Sohrab P.^ORCID,Berger Michael F.^ORCID,Arcila Maria E.,Ladanyi Marc,Levine Ross L.^ORCID,Shen Ronglai^ORCID,Razavi Pedram^ORCID,Reis-Filho Jorge S.^ORCID,Jones David R.^ORCID,Rudin Charles M.^ORCID,Isbell James M.^ORCID,Li Bob T.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-02047-z.pdf

Reference76 articles.

1. Kris, M. G. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998–2006 (2014).

2. Howlader, N. et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383, 640–649 (2020).

3. Pasche, B. & Grant, S. C. Non-small cell lung cancer and precision medicine a model for the incorporation of genomic features into clinical trial design. JAMA 311, 1975 (2014).

4. Bruno, D. S. et al. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC). J. Clin. Oncol. 39, 9005 (2021).

5. Robert, N. J. et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. J. Clin. Oncol. 39, 9004 (2021).

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro size-selection of short circulating tumor DNA fragments from late-stage lung cancer patients enhance the detection of mutations and aneuploidies;The Journal of Liquid Biopsy;2024-06

2. HER2-targeted therapies in cancer: a systematic review;Biomarker Research;2024-02-02

3. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort;JAMA Network Open;2024-01-22

4. Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan;JCO Precision Oncology;2024-01

5. A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs;Journal of Translational Medicine;2023-12-01